TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06365385

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate-last meal pattern
Description: Skyr yoghurt, whey protein and almonds over \~5 min, immediately followed by white bread, strawberry jam, banana and pulp-free orange juice over \~10 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate-last meal pattern
Description: Skyr yoghurt, whey protein and almonds over \~5 min, immediately followed by white bread, strawberry jam, banana and pulp-free orange juice over \~10 min.
Study: NCT06054815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1241
Description: Route of Administration: Oral, with subjects in a fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Route of Administration: Oral, with subjects in a fasting state
Study: NCT06365385

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate-first meal pattern
Description: White bread, strawberry jam, banana and pulp-free orange juice over \~10 min, immediately followed by skyr yoghurt, whey protein and almonds over \~5 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate-first meal pattern
Description: White bread, strawberry jam, banana and pulp-free orange juice over \~10 min, immediately followed by skyr yoghurt, whey protein and almonds over \~5 min.
Study: NCT04499950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrave
Description: Initiate Contrave at 1 tab in morning (AM) for Week 9; then 1 tab in AM and 1 tab in evening (PM) for Week 10; then 2 tab in AM and 1 tab in PM for Week 11; then 2 tab in AM and 2 tab in PM for week 12; then constant dose for months 4-6.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss
Description: 6 months of behavioral weight loss. First 3 months are weekly calls with coach and then transition to monthly calls for months 4-6.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss
Description: 6 months of behavioral weight loss. First 3 months are weekly calls with coach and then transition to monthly calls for months 4-6.
Study: NCT06262477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB800
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actemra
Description: Administered as specified in the treatment arm.
Study: NCT05087875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRAC: Tracking and Reducing Alcohol Consumption
Description: The TRAC intervention focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage alcohol consumption. Participants set goals for reducing their drinking and learn strategies to help them achieve those goals. It requires four 30-minute sessions with a counselor using mobile phones.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: The comparison group will be evaluated based on daily self-monitoring data.
Study: NCT05420064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Arm At-risk Relative/ARR Contacts
Description: Probands will give contact info for their ARR in the eDGP and indicate a date by which they will discuss the familial pathogenic variant with their ARR (can request a delay/halt to outreach). After this date the team will contact the ARR to invite them to review education and e-consent to the study. The study team will facilitate ARR cascade testing through telegenetics pre- and post-test counseling and saliva-based at home testing through MSK or a reference laboratory.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyGene Portal
Description: Through the MyGene Portal, participants will be able to continually access their genetic test results, personalized medical management recommendations from the MSK CGS care team, an interactive pedigree for personal/family history updates, and tailored educational materials for patients with a VUS in an effort to promote sustained engagement and transparency.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants will received appropriate clinical care as outline by standard of care guidelines
Study: NCT06054815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1241 Placebo
Description: Route of Administration: Oral, with subjects in a fasting state

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DA-1241 Placebo
Description: Route of Administration: Oral, with subjects in a fasting state
Study: NCT05144815

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPC + Exercise protocol
Description: The intervention consists of two parts: IPC and endurance training protocol.~IPC: participants will be placed in a supine position and a pneumatic compression cuff (Riester Komprimeter, Jungingen Germany) (96 centimetres long x 13 centimetres wide) will be placed on the proximal part of each lower extremity. Occlusion will then be performed by inflating the cuff to 220 mmHg for 5 minutes, followed by reperfusion to 0 mmHg for 5 minutes. Each session will consist of 3 sets of 5 minutes of ischaemia followed by 5 minutes of reperfusion.~Endurance training protocol: walking 20 min at moderate intensity (i.e. 64- 76 % HRmax, 12-13 Borg Scale) in a circuit designed in an open field, 3 times a week, for 6 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham IPC + Exercise protocol
Description: The intervention consists of two parts: sham IPC and endurance training protocol.~Sham IPC: the pressure cuff will be inflated by only 10 mmHg, so that it will act as a placebo.~Endurance training protocol: walking 20 min at moderate intensity (i.e. 64- 76 % HRmax, 12-13 Borg Scale) in a circuit designed in an open field, 3 times a week, for 6 weeks.
Study: NCT06054815

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DA-1241 Placebo
Description: Route of Administration: Oral, with subjects in a fasting state
Study: NCT04884698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimit Activator
Description: The Stimit Activator Device is composed of three components.~1. A magnetic stimulator generating current pulses~2. A novel Stimit coil design optimized for phrenic nerve stimulation~3. A coil positioning device for quick, easy and reproducible coil positioning
Study: NCT06054815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin Placebo
Description: Route of Administration: Oral, with subjects in a fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin Placebo
Description: Route of Administration: Oral, with subjects in a fasting state

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin Placebo
Description: Route of Administration: Oral, with subjects in a fasting state
Study: NCT05420064

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants will received appropriate clinical care as outline by standard of care guidelines
Study: NCT06054815

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin Placebo
Description: Route of Administration: Oral, with subjects in a fasting state
Study: NCT05771051

Intervention type: DEVICE
Intervention: Headpulse measurements
Description: Placement of headset on subject

Intervention type: DEVICE
Intervention: Headpulse measurements
Description: Placement of headset on subject
Study: NCT05140525

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macitentan Tablets
Description: 10 mg oral once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macitentan Tablets
Description: 10 mg oral once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riociguat
Description: 1 mg to 2.5mg oral three times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riociguat
Description: 1 mg to 2.5mg oral three times daily
Study: NCT06123468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: 10 mg/kg i.v. at day 1 and day 8 of each 21-day cycle (Q3W) for max 17 cycles (max. 12 months treatment)
Study: NCT06282848

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine 0.05%
Description: Topical application

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIMS lens
Description: Spectacle wear
Study: NCT05938179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10353 30mg oral capsules
Description: HS-10353 30mg oral capsules
Study: NCT06343441

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intraoral scan
Description: intraoral scanning of the edentulous arch and scan body

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: open tray impression
Description: conventional method of impression making with silicone rubber material
Study: NCT05121870

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: 3 does of UC-MSCs(6.0×10E7cells per time) intravenously at week 0, week 4, week 8.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline containing 1% Human serum albumin（solution without UC-MSCs）
Description: 3 does of placebo intravenously at week 0, week 4, week 8.
Study: NCT05140525

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balloon pulmonary angioplasty
Description: on hemodynamics and RV function (including advanced assessments of RV-PA coupling

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balloon pulmonary angioplasty
Description: on hemodynamics and RV function (including advanced assessments of RV-PA coupling
Study: NCT05666011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M22 IPL
Description: IPL is an attractive option in the treatment of KP as the provider can utilize cut-off filters to target both melanin for hair removal and erythema with a single device. An added benefit of IPL is the larger crystal size, allowing for efficient coverage of a larger body surface area. IPL has been utilized in the treatment of KP and KP variants, with outcomes showing reductions in both erythema and texture.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M22 IPL
Description: IPL is an attractive option in the treatment of KP as the provider can utilize cut-off filters to target both melanin for hair removal and erythema with a single device. An added benefit of IPL is the larger crystal size, allowing for efficient coverage of a larger body surface area. IPL has been utilized in the treatment of KP and KP variants, with outcomes showing reductions in both erythema and texture.
Study: NCT05091060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia HLS
Description: 56 procedure administrations with the Erchonia® HLS™ administered by the subject at home: daily procedure administrations for 8 weeks.
Study: NCT04922892

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy
Description: Total Parathyroidectomy With Autotransplantation or Total Parathyroidectomy Alone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Parathyroidectomy
Description: Total Parathyroidectomy With Autotransplantation or Total Parathyroidectomy Alone
Study: NCT06554457

Intervention type: DRUG
Intervention: Multimodal analgesia with oral strong opioids
Description: Physician's choice of post-surgical multimodal analgesia with an oral strong opioid as the backbone analgesics

Intervention type: DRUG
Intervention: Multimodal analgesia with oral strong opioids
Description: Physician's choice of post-surgical multimodal analgesia with an oral strong opioid as the backbone analgesics

Intervention type: DRUG
Intervention: Multimodal analgesia with oral strong opioids
Description: Physician's choice of post-surgical multimodal analgesia with an oral strong opioid as the backbone analgesics
Study: NCT06196476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive digital-based educational program
Description: The Interactive digital-based educational program Sessions:~Session 1: The road start to green planet: Introductory to climate change concept Session 2: Towards Climate Change Literacy Modifications: remove the cover on illiteracy.~Session 3: Green scrubs and green environment: raising climate activities and environment self-efficacy Session 4: Strengthen resilience to overcome climate related anxiety Session 5: Sustaining phase: closing session
Study: NCT05807022

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous or transbronchial argon-helium cryoablation
Description: The participants would undergo Percutaneous or transbronchial argon-helium cryoablation.
Study: NCT05938179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10353 50mg oral capsules
Description: HS-10353 50mg oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for HS-10353 30mg capsules
Description: Placebo for HS-10353 30mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for HS-10353 50mg capsules
Description: Placebo for HS-10353 50mg capsules
Study: NCT06183190

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04841226

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long-term indwelling Foley catheter
Description: Foley Catheter inserted for up to 28-days

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long-term indwelling Foley catheter
Description: Foley Catheter inserted for up to 28-days

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long-term indwelling Foley catheter
Description: Foley Catheter inserted for up to 28-days
Study: NCT05452564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 MG Oral Tablet
Description: Baricitinib, a Janus Kinase inhibitor drug for viral infections, will be administered orally to subjects randomized to this intervention. The dose will be 2 mg orally for ten weeks. This will be compared with placebo intervention. Follow up visits will take place at week 1,2,4 and 10.
Study: NCT06347471

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine
Description: Participants in the Artemether-Lumefantrine arm will be treated with standard doses of AL (Coartem, Novartis). Tablets containing 20/80 mg artemether and 120/480 mg lumefantrine will be administered per manufacturer guidelines. All doses will be given under direct supervision with fatty food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine
Description: Participants in the DHA-PPQ arm will be treated with standard doses of DHA-PPQ. Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine tablets (Eurartesim, Sigma Tau or Duocotecxin, Beijing Holley-Cotect Pharmaceutical Co) will be administered per manufacturer guidelines. All doses will be given under direct supervision on an empty stomach, as per manufacturer instructions.
Study: NCT06315088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Einkorn Diet
Description: Analysis of the oral microbiota before (T0) and after (T2) introduction of einkorn into the diet by interdental sampling, on 4 sites, pooled then analyzed by bacterial PCR.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermediate oral microbiota
Description: Comparison of the number of total bacteria and pathogens of the interdental microbiota before (T0) and in interim analysis (T1) for evaluation of the minimum period of effectiveness, by interdental sampling, on 4 sites, pooled then analyzed by bacterial PCR.
Study: NCT04704960

Intervention type: OTHER
Intervention: Diagnostic Test: liquid biopsy
Description: detection of tumor DNA alteration in cf-DNA
Study: NCT06477406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Custom formulation of a hemp-derived sublingual solution that is high in CBD and includes other cannabinoids and terpenes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An active placebo containing supplemental terpenes matched to the high-CBD product.
Study: NCT05553561

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IPRL device
Description: Intense pulsed light therapy (IPL) is a non-coherent large wavelength high-intensity light in the range of 500-1200nm. It has been used by many investigators for the treatment of evaporative dry eye safely and effectively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological therapy & Eyelid hygiene
Description: traditional methods of MGD treatment as Eyelid hygiene, topical preservative free lubricant, topical \& systemic antibiotics \& anti-inflammatory agent
Study: NCT06315088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodontal health status
Description: Analysis of the periodontal and oral clinical parameters (plaque index, gingival index, interdental inflammation, pocket depth and loss of clinical attachment, salivary pH) before (T0) and after (T2) introduction of einkorn into the diet, by sampling and periodontal analysis of all of the participants' teeth
Study: NCT06132919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC2-25 cream
Description: Topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC2-25 vehicle
Description: Topical application
Study: NCT06315088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General health status
Description: Analysis of general health indicators (body mass index, measurement of abdominal circumference, blood pressure, MOS SF-36 quality of life questionnaire and eating habits) before (T0) and after (T2) introduction of einkorn in the diet
Study: NCT04809467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafasitamab
Description: tafasitamab will be administered at a protocol defined dose once a week for cycles 1-3 and every other week from cycle 4 until progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib
Description: parsaclisib will be administered at protocol defined dose for cycles 1 through disease progression.
Study: NCT06570525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NurseNET
Description: Nurse-Delivered Narrative Exposure Therapy (NurseNET). Narrative Exposure Therapy (NET) is a brief, low-cost, trauma-focused treatment modality that is effective in treating mobile populations with complex PTSD. In NurseNET, NET is facilitated by a clinically experienced nurse, while peers/program support specialists offer scaffolded support, fostering trust, engagement, and retention. NurseNET begins with administration of a diagnostic battery and psychoeducation. Then, in subsequent NurseNET sessions, using gradual imaginative exposure, the nurse guides the participant to verbally express and re-frame their personal trauma narratives to shift unhelpful beliefs/symptoms around trauma. NurseNET utilizes a racism-conscious approach to create relational spaces in which narratives of WEH are positioned to challenge dominant social narratives. Each NurseNET session offers a brief soulfulness-based stress reduction activity to prompt emotional/affective grounding.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PAL
Description: Peer Active Listening (PAL). In the PAL active comparator/control, peers/program support specialists meet individually with participants in active listening sessions, along the same visit sequence as NurseNET. During PAL sessions, peers/program support specialists allow participants to set each conversational agenda while practicing the tenets of active listening, including attending to body language, paraphrasing the participant's verbal expressions, reflecting feelings, and using tactful repetition. PAL sessions are not intended to center on topics of trauma, but rather designed to offer a supportive relationship (attentional control).
Study: NCT05975775

Intervention type: PROCEDURE
Intervention: Laparoscopic radical prostatectomy
Description: Prostate cancer may require laparoscopic radical prostatectomy, a surgical procedure performed under general anaesthetic.
Study: NCT04510857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOVE-IT Intervention
Description: The MOVE-IT device comprises a custom smart toy and therapy game software to enable repetitive task practice involving the arm and hand.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: UCT Control
Description: Participants assigned to the UCT control group will continue to receive their previously prescribed therapy services.
Study: NCT05677126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tralement
Description: Tralement with Manganese

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fixed-dose trace element combination product of zinc, copper, and selenious acid
Description: Tralement without Manganese
Study: NCT05973851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine Nasal Product
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine hydrochloride
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Second-line Antidepressants
Description: See arm description
Study: NCT04330846

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: The type of endoscopic treatment will be initially with EBD and if a failure treatment occurred then a SEMS will be placed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: The type of endoscopic treatment will be initially with EBD and if a failure treatment occurred then a SEMS will be placed.
Study: NCT05743764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HU007
Description: cyclosporine 0.02%, trehalose 3%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restasis
Description: cyclosporine 0.05%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moisview Eye drop
Description: trehalose 3%
Study: NCT05415202

Intervention type: DRUG
Intervention: Remimazolam 20 MG [Byfavo]
Description: Remimazolam will be administered for sedation and efficacy and safety will be recorded
Study: NCT04993027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Powder
Description: Vancomycin is a bactericidal aminoglycoside antibiotic which inhibits cell wall synthesis. It is effective against gram positive bacteria. Though most commonly administered intravenously, it can be delivered orally or directly into surgical incisions and wounds in certain indications.
Study: NCT04705597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGE-175
Description: Drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05387395

Intervention type: OTHER
Intervention: NO intervention
Description: no intervention

Intervention type: OTHER
Intervention: NO intervention
Description: no intervention